After earning her doctorate Marshall moved to
GlaxoSmithKline where she joined the department of neuropharmacology. Marshall worked alongside
Patrick Humphrey and Mike Tyers at
GlaxoSmithKline. Here she investigated the receptors that are activated by neurotransmitters and microbial metabolites. After only nine years, Marshall was made Head of Molecular Pharmacology in 1999. a spin-out from the
Medical Research Council (MRC). Heptares makes use of technologies developed by the
Medical Research Council that allow the crystallisation and characterisation of
G protein-coupled receptors for drug design. This included the first crystal structure of the GLP-1 receptor. One of the cancer therapy drug candidates developed by Heptares was licensed to
AstraZeneca in 2015. Later that year, Heptares was incorporated into the Japanese bio-pharmaceutical company Sosei. Marshall joined
Merck & Co as Head of the UK Discovery Research Centre in 2018. In this capacity she concentrated on diseases of ageing. In 2019 she was made Global Head of Neuroscience Discovery, where she spent two years before being appointed Senior Vice President of Discovery, Preclinical & Translational Medicine Research. In 2022 she became the President of Biomedical Research at Novartis.
Awards and honours • 2012
WISE Campaign award for Innovation and Entrepreneurship • 2016 Elected a
Fellow of the
Academy of Medical Sciences (FMedSci) • 2018 Honorary Fellow of British Pharmacological Society
Selected publications • • • • • == References ==